erythropoietin beta

DRUG4 trials

Sponsors

University of Cambridge, University of Cologne, Hoffmann-La Roche, Assistance Publique - Hôpitaux de Paris

Conditions

Aneurysmal Subarachnoid HemorrhageHodgkin´s LymphomaHypoxic Ischemic EncephalopathyMyelodysplastic Syndromes

Phase 2

Erythropoietin Therapy for Subarachnoid Hemorrhage

CompletedNCT00140010

University of CambridgeAneurysmal Subarachnoid Hemorrhage

Start: 2005-04-30End: 2007-03-31Updated: 2009-05-20

Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma

CompletedNCT00284271

University of CologneHodgkin´s Lymphoma

Start: 2004-01-31Updated: 2011-07-29

A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.

CompletedNCT00551291

Hoffmann-La RocheMyelodysplastic Syndromes

Start: 2007-08-31End: 2009-06-30Updated: 2016-07-25

Phase 3

Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy

CompletedNCT01732146

Assistance Publique - Hôpitaux de ParisHypoxic Ischemic Encephalopathy

Start: 2013-03-28End: 2017-02-14Updated: 2025-11-20

Related Papers

Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).

2010-06-1533 citations